Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban

Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects

(2013) Charles Frost et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Oral Apixaban for the Treatment of Acute Venous Thromboembolism

(2013) Giancarlo Agnelli et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects

(2012) Charles Frost et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Prevention of VTE in Orthopedic Surgery Patients

(2012) Yngve Falck-Ytter et al.   CHEST

Apixaban for Extended Treatment of Venous Thromboembolism

(2012) Giancarlo Agnelli et al.   NEW ENGLAND JOURNAL OF MEDICINE

A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects

(2012) Jessie Wang et al.   THROMBOSIS AND HAEMOSTASIS

Apixaban in Patients with Atrial Fibrillation

(2011) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome

(2011) John H. Alexander et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays

(2010) A. HILLARP et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial

(2010) Michael Rud Lassen et al.   LANCET

Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement

(2010) Michael Rud Lassen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assays for Measuring Rivaroxaban: Their Suitability and Limitations

(2010) Edelgard Lindhoff-Last et al.   THERAPEUTIC DRUG MONITORING

Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay

(2010) Zhaoqing Wang et al.   THROMBOSIS AND HAEMOSTASIS

Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome

(2009)   CIRCULATION

Sulfation of O-Demethyl Apixaban: Enzyme Identification and Species Comparison

(2009) L. Wang et al.   DRUG METABOLISM AND DISPOSITION

Comparative Metabolism of 14C-Labeled Apixaban in Mice, Rats, Rabbits, Dogs, and Humans

(2009) D. Zhang et al.   DRUG METABOLISM AND DISPOSITION

In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies

(2009) L. Wang et al.   DRUG METABOLISM AND DISPOSITION

Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement

(2009) Michael Rud Lassen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans

(2008) N. Raghavan et al.   DRUG METABOLISM AND DISPOSITION